News stories about Immuron (NASDAQ:IMRN) have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Immuron earned a news impact score of 0.13 on Accern’s scale. Accern also gave media headlines about the company an impact score of 44.9805180307682 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Separately, HC Wainwright assumed coverage on Immuron in a report on Wednesday, October 18th. They issued a “buy” rating and a $15.00 price target for the company.

Shares of Immuron (NASDAQ:IMRN) traded up $0.03 during midday trading on Monday, hitting $5.80. The stock had a trading volume of 2,300 shares, compared to its average volume of 18,486. Immuron has a 1-year low of $4.47 and a 1-year high of $16.34.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Immuron (IMRN) Stock Price” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at

About Immuron

Immuron Limited, a microbiome company, focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that enables a shorter development therapeutic cycle.

Insider Buying and Selling by Quarter for Immuron (NASDAQ:IMRN)

Receive News & Stock Ratings for Immuron Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuron Ltd and related stocks with our FREE daily email newsletter.